Schistosomiasis
Conditions
Keywords
paediatric schistosomiasis, morbidity, immunology
Brief summary
Objective and Hypotheses: This project has the overall objective of implementing and evaluating new approaches to reducing the current and future burden of urinary schistosomiasis in young children using the antihelminthic drug Praziquantel. The project aims to (1) determine the operational health benefits of treating schistosome infections early on re-infection and morbidity reduction, (2) determine if gut or urine microbiome structure (species diversity or abundance) is a risk factor for S. haematobium infection or morbidity, and (3) elucidate the factors and underlying mechanisms mediating the reduction/reversal of schistosome-related morbidity and resistance against infection/re-infection in young children.
Detailed description
This study aims to refine current paediatric treatment of schistosomiasis using the drug Praziquantel (PZQ) to improve the current and future health of pre-school children and infants. Praziquantel is cheap, highly efficacious and safe, presenting a realistic opportunity of using a pre-existing tool in a modified way to benefit child health and development. The study will focus on children aged 3 to 5 years of age, comparing the impact of early vs. later treatment with PZQ on the current and future health status of the children. By killing worms PZQ stops the morbidity related to the presence of worms and eggs such as anaemia, abdominal pain, diarrhoea and blood in the urine as well as induced immune responses associated with reduced re-infection rates. Therefore the study will investigate the immediate health benefits of treating pre-school children and infants and the effects of treatment on re-infection rates.
Interventions
None listed
Sponsors
University of Zimbabwe
University of Edinburgh
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
3 Years to 5 Years
Healthy volunteers
Yes
Inclusion criteria
1. lifelong residents of the area 2. have provided at least 2 urine and 2 stool for parasitological examination 3. have given a blood sample before and after each treatment episode 4. be negative for schistosomes, hookworm, Trichuris and Ascaris 5. have frequent contact with infective water
Exclusion criteria
1. clinical signs of tuberculosis or malaria 2. presenting with fever 3. have had a recent major operation, illness or vaccination 4. have previously received antihelminthic treatment 5. are infected with any helminths
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Re-infection rates in children treated upon first infection compared to re-infection rates in children treated within 12 months of infection. | 12 months | Compare re-infection rates in children treated upon first infection vs. those treated within 12 months of infection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in immune measures (cytokine and antibody levels) following curative treatment | 24 months from baseline | Determine the change at 12 months post antihelminthic treatment from baseline of schistosome-specific (antibody levels) and systemic (cytokine levels) immune responses. |
| Compare the change in the gut and urine microbiome structure from baseline in children who become infected and compare to children who remain uninfected. | 12 months | Determine the change at 12 months in the gut and urine microbiome from baseline in children who become infected and compare this to the change in the same period in age and sex matched children who remain uninfected. |
| Determine the treatment-related changes in systemic (cytokine levels) and schistosome- specific ( antibody levels) immune responses in children treated upon first infection vs. those treated within 12 months of infection. | 12 months | Compare the magnitude of change from baseline in schistosome-specific (antibody levels) and systemic (cytokine levels) immune responses in children treated upon first infection to the magnitude of change from baseline in children treated within 12 months of infection at 6 weeks post-treatment |
| Reduction of morbidity (UACR and haematuria levels) levels in children treated upon first infection compared to morbidity reduction in children treated within 12 months of infection. | 12 Months | Compare magnitude of the reduction of morbidity (UACR and haematuria levels) |
Countries
Zimbabwe
Outcome results
None listed